Jardiance

Jardiance (generic name: empagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor.
Empagliflozin acts as a blocker for the SGLT2 protein in the kidney tubules, whose primary function is to reduce the amount of reabsorbed glucose and sodium in the blood. This ensures that glucose and salt are expelled through urine and not returned to the bloodstream.
As well as the effect on glucose, Jardiance reduces the heart’s workload and decreases the internal pressure inside the kidney’s filtering units.
The benefits include:

An improvement in glycemic control for adults with type 2 diabetes
A reduction in the risk of sustained kidney damage from high salt excretion
A reduction in the risks of heart failure with reduced ejection fraction.

Dosage
The prescribing doctor sets the dosage based on each patient’s underlying condition. It is essential to follow the prescribing doctor’s instructions. Before use, read the manufacturer’s Product Insert that comes with the medication.

Some side effects have been reported, such as:

• Vaginal yeast infections. Women can develop a vaginal odor, white or yellowish vaginal discharge, or vaginal itching.
• Yeast infection of the skin around the penis (balanitis)
• Nasopharyngitis
• Urinary tract infections

If these do not clear up after a few days or worsen, consult with a physician or pharmacist. Please note that not all possible side effects can be listed. If you experience any of these or any other unexpected side effects, seek medical attention promptly.